Belgian MEP proposes custom orphan drug exclusivity for innovation in untreated areas [Advocacy Lab Content]

Belgian MEP Frederique Ries has proposed tailoring market exclusivity periods for orphan drugs to foster innovation, advocating a 12-year exclusivity period for orphan drug indications lacking authorised medicinal products in the EU.